Search research articles
Contact Us
Filters
Showing results (261-270 of 315) with videos related to
Page
of 32
Sort By:
Journal of Medicinal Chemistry
|
November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells
Vassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.
Cancer Research
|
April 6, 2007
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin
Alison Maloney, Paul A Clarke, Soren Naaby-Hansen, et al.
Bioorganic & Medicinal Chemistry
|
October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B
Ian Collins, John Caldwell, Tatiana Fonseca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2018
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
Jacqueline H L Fok, Somaieh Hedayat, Lei Zhang, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Molecular Oncology
|
October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
Steven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Molecular Cancer Therapeutics
|
June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Cell Reports. Medicine
|
February 1, 2021
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity
Hadley E Sheppard, Alessandra Dall'Agnese, Woojun D Park, et al.
Journal of Medicinal Chemistry
|
October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia
Vassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
Aurélie Mallinger, Kai Schiemann, Christian Rink, et al.
Page
of 32
Search research articles
Search
Showing results (261-270 of 315) with videos related to
Sort By:
Page
of 32
Journal of Medicinal Chemistry
|
November 8, 2013
Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells
Vassilios Bavetsias, Amir Faisal, Simon Crumpler, et al.
Cancer Research
|
April 6, 2007
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin
Alison Maloney, Paul A Clarke, Soren Naaby-Hansen, et al.
Bioorganic & Medicinal Chemistry
|
October 27, 2005
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B
Ian Collins, John Caldwell, Tatiana Fonseca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2018
HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target
Jacqueline H L Fok, Somaieh Hedayat, Lei Zhang, et al.
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Molecular Oncology
|
October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
Steven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Molecular Cancer Therapeutics
|
June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Joo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Cell Reports. Medicine
|
February 1, 2021
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity
Hadley E Sheppard, Alessandra Dall'Agnese, Woojun D Park, et al.
Journal of Medicinal Chemistry
|
October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia
Vassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
ACS Medicinal Chemistry Letters
|
June 22, 2016
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19
Aurélie Mallinger, Kai Schiemann, Christian Rink, et al.
Page
of 32